8-K: Biodesix Regains Nasdaq Minimum Bid Price Compliance

Biodesix, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, resolving a previous non-compliance issue.

Summary

• Biodesix, Inc. received a letter from the Nasdaq Listing Qualifications Department on September 26, 2025, confirming it has regained compliance with the Nasdaq Listing Rule 5450(a)(1) Minimum Bid Price Requirement.
• The company was previously notified on March 24, 2025, that its common stock had closed below the $1.00 per share minimum for 30 consecutive business days.
• To regain compliance, the common stock was required to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days.
• Nasdaq has indicated that Biodesix has met this requirement, and the matter regarding the minimum bid price is now closed.

Sentiment

Score: 8

Explanation: The sentiment is highly positive as the company has resolved a significant compliance issue that could have led to delisting, thereby removing a major overhang and uncertainty for investors.

Positives

• Regained compliance with Nasdaq's minimum bid price requirement, removing the threat of delisting.
• The matter is officially closed by Nasdaq, providing certainty regarding the company's listing status.

Negatives

• Previously faced non-compliance with Nasdaq's minimum bid price requirement, indicating past stock price weakness.

Risks

• The risk of delisting from The Nasdaq Global Market due to the minimum bid price requirement has been mitigated and is now closed.

Future Outlook

The filing indicates that the matter of minimum bid price compliance is now closed, suggesting no further immediate actions are required regarding this specific listing rule.

Management Comments

• Robin Harper Cowie, Chief Financial Officer, signed the report on behalf of Biodesix, Inc.

Industry Context

Maintaining listing on a major exchange like Nasdaq is crucial for public companies to ensure liquidity, investor visibility, and access to capital markets. This resolution aligns Biodesix with standard listing requirements, which is a fundamental expectation for companies in the biotechnology and diagnostics industry.

Comparison to Industry Standards

• Maintaining a minimum bid price of $1.00 is a standard Nasdaq listing requirement (Rule 5450(a)(1)) that all listed companies must adhere to. Biodesix's regaining of compliance brings it back in line with this fundamental standard, similar to other publicly traded companies in the diagnostics sector.

Stakeholder Impact

• Shareholders: Positive impact as the risk of delisting and potential loss of liquidity for the common stock has been removed.
• Investors: Provides greater confidence and stability regarding the company's listing status on a major exchange.

Next Steps

• The matter regarding the minimum bid price requirement is now closed by Nasdaq.

Key Dates

Recommendation

The resolution of the Nasdaq minimum bid price compliance issue removes a significant negative overhang and uncertainty for Biodesix. While this is a positive development, it primarily addresses a listing requirement rather than a fundamental improvement in business operations or financial performance. Therefore, a 'hold' recommendation is appropriate, as it stabilizes the investment without necessarily indicating a strong buy signal based solely on this compliance update.

Keywords

Nasdaq compliance, minimum bid price, delisting, stock market listing, BDSX, Biodesix